Wall Street Ends Mixed as Tech and Financial Stocks Weigh on Markets Amid Thin Holiday Trading 
Asian Stock Markets Start New Year Higher as Tech and AI Shares Drive Gains 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
USDA $12 Billion Farm Aid Program Draws Mixed Reactions from Row Crop Farmers 
U.S. Dollar Starts 2026 Weak as Yen, Euro and Sterling Hold Firm Amid Rate Cut Expectations 
South Korea Exports Hit Record High as Global Trade Momentum Builds 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Forex Markets Hold Steady as Traders Await Fed Minutes Amid Thin Year-End Volumes 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
South Korean Won Slides Despite Government Efforts to Stabilize Currency Markets 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Johnson & Johnson is set to pay $230 million to settle a legal case over claims it encouraged and bolstered the opioid addiction predicament in the state of New York. Then again, it was mentioned that despite settling, the company did not acknowledge liability or any wrongdoing in what it was accused of.
What the J&J settlement means
As per BBC News, Johnson & Johnson settlement effectively prevented it from going to trial that is set to start on Tuesday, June 29. The hearing will present a number of opioid manufacturers and distributors as the defendants of the case.
The company said that its agreements with New York State are proportionate with the previous resolution to pay $5 billion to settle the opioid claims. It was added that the arrangement also requires Johnson & Johnson to discontinue the sale of painkillers across the country.
"The opioid epidemic has wreaked havoc on countless communities across New York state and the rest of the nation, leaving millions still addicted to dangerous and deadly opioids," Letitia James, the New York attorney general, said. "Johnson & Johnson helped fuel this fire, but today they're committing to leaving the opioid business - not only in New York but across the entire country."
J&J to take its problematic painkillers off the market
It was mentioned that addiction to opioids, both legal and illegal drugs, has become a serious issue, and this problem is ongoing in countries like the United States. In fact, based on the record of the Centers for Disease Control and Prevention, the country reported almost half a million deaths due to overdoses between the years 1999 and 2019.
While Johnson & Johnson is set to be removed from the trial in New York, it is still facing similar cases in other states such as California. At any rate, the deal with New York also asked the company to stop selling opioids, and it was learned that J&J already did so for some time now.
CNBC reported that Johnson & Johnson confirmed it has ended its opioid business a while ago, even before the settlement with New York. Since 2015, the company stopped marketing opioids in the U.S. and totally withdrew from the business in 2020.
